vs
Side-by-side financial comparison of FOX FACTORY HOLDING CORP (FOXF) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
FOX FACTORY HOLDING CORP is the larger business by last-quarter revenue ($376.4M vs $177.4M, roughly 2.1× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -0.2%, a 1.8% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 4.8%). Over the past eight quarters, FOX FACTORY HOLDING CORP's revenue compounded faster (6.4% CAGR vs -0.2%).
Fox Factory Holding Corp. is an American company best known for their Fox Racing Shox brand of off-road racing suspension components.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FOXF vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $376.4M | $177.4M |
| Net Profit | $-634.0K | $2.9M |
| Gross Margin | 30.4% | — |
| Operating Margin | 4.0% | 3.9% |
| Net Margin | -0.2% | 1.6% |
| Revenue YoY | 4.8% | 5.0% |
| Net Profit YoY | -113.3% | — |
| EPS (diluted) | $-0.02 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $376.4M | $196.9M | ||
| Q3 25 | $374.9M | $179.5M | ||
| Q2 25 | $355.0M | $181.1M | ||
| Q1 25 | $352.8M | $168.9M | ||
| Q4 24 | — | $187.3M | ||
| Q3 24 | $359.1M | $168.6M | ||
| Q2 24 | $348.5M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-634.0K | — | ||
| Q3 25 | $2.7M | $5.4M | ||
| Q2 25 | $-259.7M | $-4.8M | ||
| Q1 25 | $-141.0K | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $4.8M | $-143.5M | ||
| Q2 24 | $5.4M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 30.4% | 79.5% | ||
| Q3 25 | 31.2% | 80.9% | ||
| Q2 25 | 30.9% | 77.4% | ||
| Q1 25 | 28.9% | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | 29.9% | 76.9% | ||
| Q2 24 | 31.8% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 4.0% | 1.2% | ||
| Q3 25 | 4.9% | 3.5% | ||
| Q2 25 | -70.6% | 4.7% | ||
| Q1 25 | 3.2% | 1.2% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | 5.2% | -82.8% | ||
| Q2 24 | 5.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -0.2% | — | ||
| Q3 25 | 0.7% | 3.0% | ||
| Q2 25 | -73.1% | -2.7% | ||
| Q1 25 | -0.0% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.3% | -85.1% | ||
| Q2 24 | 1.6% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.02 | $0.05 | ||
| Q3 25 | $0.07 | $0.12 | ||
| Q2 25 | $-6.23 | $-0.11 | ||
| Q1 25 | $0.00 | $0.10 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $0.11 | $-3.11 | ||
| Q2 24 | $0.13 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | $536.7M | — |
| Stockholders' EquityBook value | $956.0M | $653.9M |
| Total Assets | $2.0B | $1.2B |
| Debt / EquityLower = less leverage | 0.56× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | $71.7M | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $536.7M | $372.2M | ||
| Q3 25 | $541.8M | $376.7M | ||
| Q2 25 | $546.9M | $580.5M | ||
| Q1 25 | $552.1M | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | $558.4M | — | ||
| Q2 24 | $564.1M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $956.0M | $693.1M | ||
| Q3 25 | $958.7M | $727.2M | ||
| Q2 25 | $939.9M | $757.8M | ||
| Q1 25 | $1.2B | $798.5M | ||
| Q4 24 | — | $778.3M | ||
| Q3 24 | $1.2B | $749.6M | ||
| Q2 24 | $1.2B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $2.0B | $1.3B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $2.2B | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $2.3B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.56× | 0.54× | ||
| Q3 25 | 0.57× | 0.52× | ||
| Q2 25 | 0.58× | 0.77× | ||
| Q1 25 | 0.46× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.47× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.3M | — |
| Free Cash FlowOCF − Capex | $-2.5M | — |
| FCF MarginFCF / Revenue | -0.7% | — |
| Capex IntensityCapex / Revenue | 2.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $85.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $5.3M | $43.7M | ||
| Q3 25 | $36.8M | $60.8M | ||
| Q2 25 | $680.0K | $12.0M | ||
| Q1 25 | $81.7M | $35.5M | ||
| Q4 24 | — | $33.1M | ||
| Q3 24 | $14.1M | $53.9M | ||
| Q2 24 | $26.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-2.5M | $43.5M | ||
| Q3 25 | $24.6M | $57.0M | ||
| Q2 25 | $-6.5M | $9.3M | ||
| Q1 25 | $69.8M | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $3.2M | $49.8M | ||
| Q2 24 | $15.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -0.7% | 22.1% | ||
| Q3 25 | 6.6% | 31.7% | ||
| Q2 25 | -1.8% | 5.1% | ||
| Q1 25 | 19.8% | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | 0.9% | 29.6% | ||
| Q2 24 | 4.4% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.1% | ||
| Q3 25 | 3.3% | 2.2% | ||
| Q2 25 | 2.0% | 1.5% | ||
| Q1 25 | 3.4% | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | 3.0% | 2.4% | ||
| Q2 24 | 3.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 13.41× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.94× | — | ||
| Q2 24 | 4.94× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOXF
| Specialty Sports Group | $132.7M | 35% |
| Powered Vehicles Group | $125.9M | 33% |
| Aftermarket Applications Group | $117.8M | 31% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
